WO2007141799A1 - A process for preparing pure anastrozole - Google Patents

A process for preparing pure anastrozole Download PDF

Info

Publication number
WO2007141799A1
WO2007141799A1 PCT/IN2006/000338 IN2006000338W WO2007141799A1 WO 2007141799 A1 WO2007141799 A1 WO 2007141799A1 IN 2006000338 W IN2006000338 W IN 2006000338W WO 2007141799 A1 WO2007141799 A1 WO 2007141799A1
Authority
WO
WIPO (PCT)
Prior art keywords
anastrozole
triazol
related substances
isobutyramide
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000338
Other languages
French (fr)
Inventor
Kirtipalsinh Sajjansinh Solanki
Manoj Kumar Singh
Jay Shantilal Kothari
Virendra Kumar Agarwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to EP06842740A priority Critical patent/EP2029557A1/en
Priority to US12/303,235 priority patent/US8058302B2/en
Publication of WO2007141799A1 publication Critical patent/WO2007141799A1/en
Anticipated expiration legal-status Critical
Priority to US12/952,707 priority patent/US20110065927A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • Aromatase is an enzyme, which effects aromatisation of ring A in the metabolic formation of various steroid hormones.
  • Various cancers for example, breast cancer are dependent upon circulating steroid hormones, which have an aromatic ring A.
  • Such cancers can be treated by removing the source of ring A aromatised steroid hormones, for example, by the combination of oophorectomy and adrenalectomy.
  • An alternative way of obtaining the same effect is by administering a chemical compound, which inhibits the aromatisation of the steroid ring A.
  • Anastrozole is a non-steroidal antineoplastic, claimed to inhibit the aromatase (oestrogen synthase) activity. It is useful in the treatment of advanced breast cancer in postmenopausal women. BACKGROUND OF INVENTION
  • DISCRIPTION OF INVENTION Intermediate (3) undergoes condensation with 4-amino-l,2,4-triazole (4) in a suitable solvent to give 4-amino-l-[3,5-bis-(l-cyano-l-methylethyl)benzyl]-lH- [l,2,4]triazolium bromide (Q.A.-salt) (5) in good yield.
  • hydrolysis of cyano groups also takes place leading to the formation of two major related substances.
  • the hydrolysis products formed due to hydrolysis are characterized as 2- [3 -(cyanodimethyl-methyl)-5 - [ 1 ,2,4]triazol- 1 -ylmethyl-phenyl] -isobutyramide (6) and 2-[3 -( 1 -carbamoyl- 1 -methylethyl)-5 - [ 1 ,2,4]triazol- 1 -ylmethylphenyl] - isobutyramide (7). Both the substances are isolated and well characterized by using NMR and mass analysis.
  • the HPLC chromatogram of Anastrozole shows presence of related substances (6) and (7) in 0.02 % to 1.0 % in crude product which are removed by the repeated crystallization using an alcoholic solvent with a mixture of hydrocarbon as anti-solvent.
  • the removal of the related substances 2-[3-(cyanodimethyl-methyl)-5-
  • [l,2,4]triazol-l-ylmethyl-phenyl]-isobutyramide (6) and 2-[3-(l-carbamoyl-l- methylethyl) : 5-[l,2,4]triazol-l-ylmemylphenyl]-isobutyramide (7) are accomplished by the crystallization method using various solvent systems to get Anastrozole in its purer form.
  • the main embodiment of the present invention relates to the products 2- [3- (cyanodimethyl-methyl)-5-[l,2,4]triazol-l-ylmethyl-phenyl]-isobutyramide (6) and 2- [3 -( 1 -carbamoyl- 1 -methy lethyl)-5 -[ 1 ,2,4]triazol- 1 -ylmethylphenyl] -isobutyramide (7) as related substances in Anastrozole.
  • the present invention also relates to the process for the preparation of Anastrozole with related substances 2-[3-(cyanodimethyl-methyl)-5-[l,2,4]triazol-l-ylmethyl-phenyl]- isobutyramide (6) and 2-[3-(l-carbamoyl-l-methylethyl)-5-[l,2,4]triazol-l- ylmethylphenyl] -isobutyramide (7) preferably, less than 1.0%, more preferably, 0.1% and most preferably, below quantitation limits.
  • Anastrozole is obtained in its purer form but still some extent of the related substances 2-[3-(cyanodimethyl-methyl)-5- [l,2,4]triazol-l-ylmethyl-phenyl]-isobutyramide (6) and 2-[3-(l-carbamoyl-l- methylethyl)-5-[l,2,4]triazol-l-ylmethylphenyl]-isobutyramide (7) still remain contaminating Anastrozole, which is further purified using organic solvents preferably isopropanol, ethyl acetate or mixture of solvents preferably cyclohexane/ethyl acetate, cyclohexane/isopropanol or a mixture of solvents with water.
  • organic solvents preferably isopropanol, ethyl acetate or mixture of solvents preferably cyclohexane/ethyl acetate, cyclohexane/is
  • Another embodiment of the present invention relates to the process for the preparation of Anastrozole free from related substances (6) and (7) by crystallization of crude Anastrozole using alcohols preferably selected from Cl to ClO alcohols and hydrocarbons, preferably selected from aliphatic hydrocarbons preferably Cl to ClO.
  • Alcohols preferably selected from Cl to ClO alcohols and hydrocarbons, preferably selected from aliphatic hydrocarbons preferably Cl to ClO.
  • Example - 1 2,2'-[5-(lH-l,2,4-Triazol-l-ylmethyl)-l,3-phenylene]di(2-methylpropiononitrile) (1), Anastrozole
  • reaction mixture was quenched by the addition of a solution of urea (4.5 g) in water (15 mL). Toluene (700 mL) was added to the reaction mixture and the heterogeneous solution was further cooled down to 0 - 5 0 C. The solution was basified by the addition of liquor ammonia (365 mL) slowly in 4 hours at 5 - 25 0 C. Organic layer was separated and further washed with water (200 mL). Aqueous layer was removed and a solution of cone. HCl (140 mL) in water (140 mL) was added to the organic layer slowly in 30 minutes at 25 - 30 0 C and reaction mass was heated at 60 - 65 0 C for 30 minutes.
  • the lower aqueous layer (280 - 300 mL), containing product was collected in a conical flask maintaining at 50 0 C.
  • the aqueous part was again washed with toluene (700 mL) at 60 - 65 0 C for 30 minutes.
  • the lower aqueous layer, containing product was charged in a separating funnel and again washed with fresh toluene (700 mL).
  • the aqueous layer, containing product was transferred in a R.B. flask and ethyl acetate (350 mL) was added to it.
  • the heterogeneous solution was cooled to 0 - 5 0 C basified by the slow addition of liquor ammonia (280 mL) in 2 - 3 hours at 5 - 25 0 C.
  • the solution was stirred for one hour at 25 - 35 0 C, and the upper organic layer (360 - 375 mL), containing product was separated and filtered through hyflow super cell bed.
  • Solvent was distilled out below 50 0 C under vacuum leaving approximately 100 mL ethyl acetate in the flask.
  • the content of the flask was cooled down to 25 - 35 0 C and cyclohexane (500 mL) was added to the solution slowly in 30 minutes.
  • Anastrozole (33 g) from example - 2 was dissolved in isopropanol (100 mL) at 45 - 50 0 C. The solution was cooled down to 25 - 35 0 C and cyclohexane (100 mL) was added drop wise in 30 minutes. The solution was stirred at 25 - 35 0 C for 2 hours; the precipitated solid product was filtered and washed with fresh cyclohexane (30 mL x 2) and dried at 50 0 C to get 23 g of pure Anastrozole contaminated with related substance (6) as 0.09% and with related substance (7) below detection limit.
  • Example - 3
  • Pure Anastrozole (11 g) from Example - 2 was further purified by dissolving in isopropanol (33 mL) at 45 - 50 0 C. The solution was cooled down to 25 - 35 0 C and cyclohexane (33 mL) was added drop wise in 30 minutes. The solution was stirred at 25 - 35 0 C for 2 hours; the precipitated solid product was filtered and washed with fresh cyclohexane (30 mL x 2) and dried at 50 0 C to get 8.9 g of pure Anastrozole containing with 0.03% of (6) as related substance and another related substance (7) below detection limit. Related substance (6) can be further removed below detection limit by repeating the same process.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention discloses two new related substances (6) and (7) of Anastrozole synthesis from Q.A. Salt (5) as in Scheme - 1 and purification procedures to get Anastrozole (1) free from (6) and (7).

Description

A PROCESS FOR PREPARING PURE ANASTROZOLE
FIELD OF INVENTION
Aromatase is an enzyme, which effects aromatisation of ring A in the metabolic formation of various steroid hormones. Various cancers, for example, breast cancer are dependent upon circulating steroid hormones, which have an aromatic ring A. Such cancers can be treated by removing the source of ring A aromatised steroid hormones, for example, by the combination of oophorectomy and adrenalectomy. An alternative way of obtaining the same effect is by administering a chemical compound, which inhibits the aromatisation of the steroid ring A.
Anastrozole is a non-steroidal antineoplastic, claimed to inhibit the aromatase (oestrogen synthase) activity. It is useful in the treatment of advanced breast cancer in postmenopausal women. BACKGROUND OF INVENTION
Synthesis of Anastrozole is reported in US 4,935,437 and European Patent Application EP 0,296,749. The synthetic route mentioned in the said patents suffers a major disadvantage of the formation of Anastrozole regioisomer (2).
Figure imgf000002_0001
ANASTROZOLE REGIOISOMER
To overcome the formation of regioisomer (2), another synthetic route is reported in US Patent No. 4,935,437; in which compound (3) is reacted with 4-amino-
1,2,4-triazole (4) to form quaternary ammonium salt (5), which further undergoes diazotisation reaction to give Anastrozole (1) free from regioisomeric impurity (2)
(Scheme - 1).
-l-
Figure imgf000003_0001
It has been observed that the cyano groups undergo hydrolysis in various conditions to form hydrolysed related compounds. OBJECTS OF THE INVENTION
It is an object of the present invention to provide an improved process for the preparation of pure Anastrozole (1) free from impurities arising due to hydrolysis of cyano groups during the course of the preparation of Anastrozole (1). DISCRIPTION OF INVENTION Intermediate (3) undergoes condensation with 4-amino-l,2,4-triazole (4) in a suitable solvent to give 4-amino-l-[3,5-bis-(l-cyano-l-methylethyl)benzyl]-lH- [l,2,4]triazolium bromide (Q.A.-salt) (5) in good yield.
It has been further observed that during the preparation of Anastrozole, hydrolysis of cyano groups also takes place leading to the formation of two major related substances. The hydrolysis products formed due to hydrolysis are characterized as 2- [3 -(cyanodimethyl-methyl)-5 - [ 1 ,2,4]triazol- 1 -ylmethyl-phenyl] -isobutyramide (6) and 2-[3 -( 1 -carbamoyl- 1 -methylethyl)-5 - [ 1 ,2,4]triazol- 1 -ylmethylphenyl] - isobutyramide (7). Both the substances are isolated and well characterized by using NMR and mass analysis. The 1H-NMR, 13C-NMR and mass analysis of the isolated products 2-[3 -(cyanodimethyl-methyl)-5 - [ 1 ,2,4]triazol- 1 -ylmethyl-phenyl] - isobutyramide (6) and 2-[3-(l-carbamoyl-l-methylethyl)-5-[l,2,4]triazol-l- ylmethylphenyl] -isobutyramide (7) are in accordance with the chemical structure. 1H- NMR of compound (6) shows three singlets at δ 7.4, 7.3 and 7.24 for three protons in aromatic ring, and two protons at δ 6.95 for amide group. However four methyl groups appear at δ 1.65 and 1.41, each for six protons. The 13C-NMR of compound (6) shows a quaternary peak at δ 177.4 for amide carbonyl carbon, three tertiary aromatic carbons at δ 125.0, 122.7 and 122.2; two aliphatic quaternary carbons at δ 52.1 and 46.1 and two peaks for methyl carbons at δ 28.4 and 26.7. Further, the structure is also confirmed by the mass analysis of compound (6).
Figure imgf000004_0001
(6) 2-[3-(Cyano-dimethyl-methyl)-5-[1 ,2,4]triazol-1-ylmethyl-phenyl]-isobutyramide
The IH-NMR of compound (7) shows peaks at δ 6.86 for amide protons and its 13C-NMR shows amide carbonyl carbon at δ 179.6. Further, the structure is also confirmed by the mass analysis of compound (7).
Figure imgf000004_0002
(7) 2-[3-(1-Carbamoyl-1-methylethyl)-5-[1 ,2,4]triazol-1-ylmethylphenyl]-isobutyramide
The HPLC chromatogram of Anastrozole shows presence of related substances (6) and (7) in 0.02 % to 1.0 % in crude product which are removed by the repeated crystallization using an alcoholic solvent with a mixture of hydrocarbon as anti-solvent. The removal of the related substances 2-[3-(cyanodimethyl-methyl)-5-
[l,2,4]triazol-l-ylmethyl-phenyl]-isobutyramide (6) and 2-[3-(l-carbamoyl-l- methylethyl):5-[l,2,4]triazol-l-ylmemylphenyl]-isobutyramide (7) are accomplished by the crystallization method using various solvent systems to get Anastrozole in its purer form. Thus, the main embodiment of the present invention relates to the products 2- [3- (cyanodimethyl-methyl)-5-[l,2,4]triazol-l-ylmethyl-phenyl]-isobutyramide (6) and 2- [3 -( 1 -carbamoyl- 1 -methy lethyl)-5 -[ 1 ,2,4]triazol- 1 -ylmethylphenyl] -isobutyramide (7) as related substances in Anastrozole. According to another embodiment, the present invention also relates to the process for the preparation of Anastrozole with related substances 2-[3-(cyanodimethyl-methyl)-5-[l,2,4]triazol-l-ylmethyl-phenyl]- isobutyramide (6) and 2-[3-(l-carbamoyl-l-methylethyl)-5-[l,2,4]triazol-l- ylmethylphenyl] -isobutyramide (7) preferably, less than 1.0%, more preferably, 0.1% and most preferably, below quantitation limits. NMR data of Anastrozole (1) and related substances (6) and (7)
Figure imgf000005_0001
Following the procedures as per Scheme - 1 Anastrozole is obtained in its purer form but still some extent of the related substances 2-[3-(cyanodimethyl-methyl)-5- [l,2,4]triazol-l-ylmethyl-phenyl]-isobutyramide (6) and 2-[3-(l-carbamoyl-l- methylethyl)-5-[l,2,4]triazol-l-ylmethylphenyl]-isobutyramide (7) still remain contaminating Anastrozole, which is further purified using organic solvents preferably isopropanol, ethyl acetate or mixture of solvents preferably cyclohexane/ethyl acetate, cyclohexane/isopropanol or a mixture of solvents with water. Thus another embodiment of the present invention relates to the process for the preparation of Anastrozole free from related substances (6) and (7) by crystallization of crude Anastrozole using alcohols preferably selected from Cl to ClO alcohols and hydrocarbons, preferably selected from aliphatic hydrocarbons preferably Cl to ClO. Example - 1 2,2'-[5-(lH-l,2,4-Triazol-l-ylmethyl)-l,3-phenylene]di(2-methylpropiononitrile) (1), Anastrozole
4- Amino- 1 -[3 , 5 -bis-( 1 -cyano- 1 -methylethyl)benzyl] -IH-[1 ,2,4]triazolium bromide (5) (70 g) was dissolved in cone. HCl (280 mL) in a 5 L R.B. flask and cooled to -5 0C. A solution of sodium nitrite (15 g) in water (70 mL) was slowly added to the reaction mixture at 0 - 5 0C in 4 hrs and the reaction mixture was stirred for one hour at 0 - 5 0C and further at 10 - 20 0C for next 3 hours. The reaction mixture was quenched by the addition of a solution of urea (4.5 g) in water (15 mL). Toluene (700 mL) was added to the reaction mixture and the heterogeneous solution was further cooled down to 0 - 5 0C. The solution was basified by the addition of liquor ammonia (365 mL) slowly in 4 hours at 5 - 25 0C. Organic layer was separated and further washed with water (200 mL). Aqueous layer was removed and a solution of cone. HCl (140 mL) in water (140 mL) was added to the organic layer slowly in 30 minutes at 25 - 30 0C and reaction mass was heated at 60 - 65 0C for 30 minutes. The lower aqueous layer (280 - 300 mL), containing product was collected in a conical flask maintaining at 50 0C. The aqueous part was again washed with toluene (700 mL) at 60 - 65 0C for 30 minutes. The lower aqueous layer, containing product was charged in a separating funnel and again washed with fresh toluene (700 mL). The aqueous layer, containing product was transferred in a R.B. flask and ethyl acetate (350 mL) was added to it. The heterogeneous solution was cooled to 0 - 5 0C basified by the slow addition of liquor ammonia (280 mL) in 2 - 3 hours at 5 - 25 0C. The solution was stirred for one hour at 25 - 35 0C, and the upper organic layer (360 - 375 mL), containing product was separated and filtered through hyflow super cell bed. Solvent was distilled out below 50 0C under vacuum leaving approximately 100 mL ethyl acetate in the flask. The content of the flask was cooled down to 25 - 35 0C and cyclohexane (500 mL) was added to the solution slowly in 30 minutes. The precipitated solid product was filtered and washed with fresh cyclohexane (20 mL x 2). The product was dried at 45 - 50 0C to get crude Anastrozole (44 g) with more than 98% HPLC purity contaminated with related substance (6) as 0.36% and with related substance (7) as 0.05%. Example - 2 Removal of Related substances (6) and (7) from Anastrozole
Anastrozole (33 g) from example - 2 was dissolved in isopropanol (100 mL) at 45 - 50 0C. The solution was cooled down to 25 - 35 0C and cyclohexane (100 mL) was added drop wise in 30 minutes. The solution was stirred at 25 - 35 0C for 2 hours; the precipitated solid product was filtered and washed with fresh cyclohexane (30 mL x 2) and dried at 50 0C to get 23 g of pure Anastrozole contaminated with related substance (6) as 0.09% and with related substance (7) below detection limit. Example - 3
Purification of Anastrozole
Pure Anastrozole (11 g) from Example - 2 was further purified by dissolving in isopropanol (33 mL) at 45 - 50 0C. The solution was cooled down to 25 - 35 0C and cyclohexane (33 mL) was added drop wise in 30 minutes. The solution was stirred at 25 - 35 0C for 2 hours; the precipitated solid product was filtered and washed with fresh cyclohexane (30 mL x 2) and dried at 50 0C to get 8.9 g of pure Anastrozole containing with 0.03% of (6) as related substance and another related substance (7) below detection limit. Related substance (6) can be further removed below detection limit by repeating the same process.

Claims

We claim:
1. Compounds (6) and (7) as related substances in Anastrozole
Figure imgf000008_0001
(6)
2. Crude Anastrozole with compounds of structural formulae (6) and (7)
Figure imgf000008_0002
as impurities, present preferably in amounts less than 1.0% more preferably, less than 0.1% and most preferably below quantitation limits.
3. A process for producing pure Anastrozole by the removal of related substances of structural formula (6) and (7) from Anastrozole, comprising: a) dissolving Anastrozole in an alcoholic solvent b) adding hydrocarbon to the alcoholic solution and c) isolating pure Anastrozole.
4. A process as claimed in claim 3 wherein the alcoholic solvents used are selected from Cl - C6 straight chain, branched or cyclic alcohols.
5. A process as claimed in claim 3, wherein the hydrocarbons used as anti-solvent are selected from aromatic or aliphatic hydrocarbons; preferably selected from Cl - ClO, straight chain, branched or cyclic hydrocarbons.
PCT/IN2006/000338 2006-06-05 2006-09-04 A process for preparing pure anastrozole Ceased WO2007141799A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06842740A EP2029557A1 (en) 2006-06-05 2006-09-04 A process for preparing pure anastrozole
US12/303,235 US8058302B2 (en) 2006-06-05 2006-09-04 Process for preparing pure anastrozole
US12/952,707 US20110065927A1 (en) 2006-06-05 2010-11-23 Process for preparing pure anastrozole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN865-MUM-2006 2006-06-05
IN865MU2006 2006-06-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/303,235 A-371-Of-International US8058302B2 (en) 2006-06-05 2006-09-04 Process for preparing pure anastrozole
US12/952,707 Division US20110065927A1 (en) 2006-06-05 2010-11-23 Process for preparing pure anastrozole

Publications (1)

Publication Number Publication Date
WO2007141799A1 true WO2007141799A1 (en) 2007-12-13

Family

ID=38068935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000338 Ceased WO2007141799A1 (en) 2006-06-05 2006-09-04 A process for preparing pure anastrozole

Country Status (3)

Country Link
US (2) US8058302B2 (en)
EP (1) EP2029557A1 (en)
WO (1) WO2007141799A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7692025B2 (en) 2005-04-06 2010-04-06 Sicor, Inc. Process for the preparation of anticancer drugs
WO2009010991A3 (en) * 2007-07-17 2010-11-11 Ind-Swift Laboratories Limited Purification process to prepare highly pure anastrozole
CN106083748A (en) * 2016-06-21 2016-11-09 扬子江药业集团江苏海慈生物药业有限公司 A kind of preparation method of Anastrozole

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for preparing and using endoxifen
JP7662204B2 (en) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド Sustained release compositions of endoxifen

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296749A1 (en) * 1987-06-16 1988-12-28 Zeneca Limited (Substituted aralkyl) heterocyclic compounds
WO2005105762A1 (en) * 2004-05-05 2005-11-10 Natco Pharma Limited Improved process for the preparation of high purity anastrozole
US20060035950A1 (en) * 2004-08-09 2006-02-16 Mohammed Alnabari Novel processes for preparing substantially pure anastrozole
US20060189670A1 (en) * 2005-02-22 2006-08-24 Glenmark Pharmaceuticals Limited Process for the preparation of anastrozole and intermediates thereof
WO2006108155A2 (en) * 2005-04-06 2006-10-12 Sicor, Inc. Process for the preparation of anastrozole
WO2007002720A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296749A1 (en) * 1987-06-16 1988-12-28 Zeneca Limited (Substituted aralkyl) heterocyclic compounds
WO2005105762A1 (en) * 2004-05-05 2005-11-10 Natco Pharma Limited Improved process for the preparation of high purity anastrozole
US20060035950A1 (en) * 2004-08-09 2006-02-16 Mohammed Alnabari Novel processes for preparing substantially pure anastrozole
US20060189670A1 (en) * 2005-02-22 2006-08-24 Glenmark Pharmaceuticals Limited Process for the preparation of anastrozole and intermediates thereof
WO2006108155A2 (en) * 2005-04-06 2006-10-12 Sicor, Inc. Process for the preparation of anastrozole
WO2007002720A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANG GU PING ET AL: "2-Ä3-(2-CYANO-2-PROPYL)-5-(1,2,4-TRIAZOL-1-YLMETHYL)PHENYLÜ-2- METHYLPROPIONONITRILE", ACTA CRYSTALLOGRAPHICA, SECTION E: STRUCTURE REPORTS ONLINE, XX, XX, vol. E61, no. 8, 2005, pages O2330 - O2331, XP008074863, ISSN: 1600-5368 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7692025B2 (en) 2005-04-06 2010-04-06 Sicor, Inc. Process for the preparation of anticancer drugs
WO2009010991A3 (en) * 2007-07-17 2010-11-11 Ind-Swift Laboratories Limited Purification process to prepare highly pure anastrozole
CN106083748A (en) * 2016-06-21 2016-11-09 扬子江药业集团江苏海慈生物药业有限公司 A kind of preparation method of Anastrozole
CN106083748B (en) * 2016-06-21 2019-08-16 扬子江药业集团江苏海慈生物药业有限公司 A kind of preparation method of Anastrozole

Also Published As

Publication number Publication date
EP2029557A1 (en) 2009-03-04
US20090247765A1 (en) 2009-10-01
US8058302B2 (en) 2011-11-15
US20110065927A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
US12049457B2 (en) Highly purified pharmaceutical grade tasimelteon
EP0676409A1 (en) Erythromycin derivatives, their process for preparation and their application as medicaments
WO2016016766A2 (en) A process for the preparation of isavuconazonium or its salt thereof
US20110065927A1 (en) Process for preparing pure anastrozole
WO2012146980A2 (en) Preparation of fingolimod and its salts
AU2016261273A1 (en) Process for the preparation of efinaconazole
US9273010B2 (en) Process for bendamustine hydrochloride
CA2800946C (en) Crystal delta form of arginine perindopril salt, its preparation process and the pharmaceutical compounds containing same
EP2240436A1 (en) Novel process for the preparation of vorinostat
EP3436439B1 (en) Process for the preparation of diphenylpyrazine derivatives
CN105085524A (en) Preparation method of high purity valganciclovir hydrochloride
CN104961787B (en) Synthetic method of cordycepin
CN120209051A (en) Targeted compounds for delivery and their uses
EP4303211B1 (en) Industrial process for the preparation of hexanoic acid, 6(nitrooxy)-,(1s,2e)-3-[(1r,2r,3s,5r)-2-[(2z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]3,5-dihydroxycyclopentyl]-1-(2-phenyl ethyl)-2-propen-1-yl ester and high pure product
FR2749585A1 (en) NOVEL AROMATIC DERIVATIVES SUBSTITUTED BY RIBOSIS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
EP1940806A2 (en) A process for the preparation of pure anastrozole
CN110698335A (en) Synthesis method of terbutaline intermediate
CN1878741A (en) Novel polymorphs of atovaquone and process of preparation thereof
CN113004202B (en) A kind of preparation method of high-purity tolvaptan
MD4303211T2 (en) Industrial process for the preparation of hexanoic acid, 6(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]3,5-dihydroxycyclopentyl]-1-(2-phenyl ethyl)-2-propen-1-yl ester and high pure product
EP4524138A1 (en) Method for preparing glucopyranosyl-containing compound
CN114573557A (en) Preparation method of ultraconazole
CN112142804A (en) Preparation method of decitabine
EA044433B1 (en) SYNTHESIS OF A 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYLBENZYL)-4-(β-D-Glucopyranose-1-YL)BENZENE, L-PROLINE AND WATER
WO2008107777A2 (en) Improved method for the preparation of desloratadine with reduced levels of organic solvents

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06842740

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2006842740

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12303235

Country of ref document: US